Thrombolytic therapy for acute ischemic stroke

Canadian Journal of Emergency Medicine

Volumn 3, Issue 1, 2001, Pages 8-12

  Rutledge, Tim ^a   Bergmann, Terence ^b   Cass, Dan ^c   Dreyer, Jonathan ^d   Dubinsky, Isser ^e   Ducharme, Jim ^f   Findlater, Jane ^g   Fisher, Harold ^h   Greenway, Keith ⁱ   Hoag, Roger ^j   McCallum, Andrew ^k   Murray, Michael ^l   O'Connor, Michael ^m   Ovens, Howard ^h   Palatnick, Wes ⁿ   Robson, Robert ^o   Sinclair, Doug ^p   Squires, Jim ^q   Taylor, Tony ^r   Thompson, Jim ^s   Topping, Claude ^t   Vandersluis, Rudy ^u   Weitzman, Brian ^v   Zeit, Harry ^w   more..

^a NORTH YORK GENERAL HOSPITAL   (Canada)

^b Grace Hospital Winnipeg   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f SAINT JOHN REGIONAL HOSPITAL   (Canada)

^g Everett Chambers Hospital   (Canada)

^h MOUNT SINAI HOSPITAL   (Canada)

ⁱ Brampton Civic Hospital   (Canada)

^j Queensway Carleton Hospital   (Canada)

^k HAMILTON HEALTH SCIENCES   (Canada)

^l Royal Victoria Hospital Barrie   (Canada)

^m HOTEL DIEU HOSPITAL   (Canada)

ⁿ HEALTH SCIENCES CENTRE   (Canada)

^o Orleans Urgent Care Clinic   (Canada)

^p QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^q Guelph General Hospital   (Canada)

^r FOOTHILLS HOSPITAL   (Canada)

^s Prince Edward Island   (Canada)

^t LAVAL UNIVERSITY   (Canada)

^u LAKERIDGE HEALTH CORPORATION   (Canada)

^v UNIVERSITY OF OTTAWA   (Canada)

^w Cambridge Memorial Hospital   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0003186337     PISSN: 14818035     EISSN: 14818035     Source Type: Journal    
DOI: 10.1017/s148180350000508x     Document Type: Article

References (18)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333(24):1581-7.
2. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Lancet 1995;346:1509-14.
3. Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicenter Acute Stroke Trial - Europe Study Group. N Engl J Med 1996;335:145-50.
4. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, et al. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996;276:961-6.
5. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study. JAMA 1995;274:1017-25.
6. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-51.
7. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II Study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003-11.
8. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;282(21):2019-26.
9. Norris JW, Buchan A, Cote R, Hachinski V, Phillips SJ, Shuaib A, et al. Canadian guidelines for intravenous thrombolytic treatment in acute stroke. A consensus statement of the Canadian Stroke Consortium. Can J Neurol Sci 1998;25(3):257-9.
10. von Kummer R, Allen KL, Holle R, Bozzao L, Bastianello S, Manelfe C, et al. Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology 1997;205:327-33.
11. Schriger DL, Kalafut M, Starkman S, Krueger M, Saver JL. Cranial computed tomography interpretation in acute stroke: physician accuracy in determining eligibility for thrombolytic therapy. JAMA 1998;279:1293-7.
12. O'Connor RE, McGraw P, Edelsohn L. Thrombolytic therapy for acute ischemic stroke: why the majority of patients remain ineligible for treatment. Ann Emerg Med 1999;33:9-14.
13. Zweifler RM, Drinkard R, Cunningham S, Brody ML, Rothrock JF. Implementation of a stroke code system in Mobile, Alabama: diagnostic and therapeutic yield. Stroke 1997;28:981-3.
14. Libman RB, Wirkowski E, Alvir J, Rao TH. Conditions that mimic stroke in the emergency department: implications for acute stroke trials. Arch Neurol 1995;52(11):1119-22.
15. Leys D, Lucas C, Devos D, Mounier-VehierF, Godefroy O, Pruvo JP, et al. Misdiagnoses in 1,250 consecutive patients admitted to an acute stroke unit. Cerebrovasc Dis 1997;7 (Suppl 5):284-8.
16. Allder SJ, Moody AR, Martel AL, Morgan PS, Delay GS, Gladman JR. Limitations of clinical diagnosis in acute stroke. Lancet 1999;354:1523-6.
17. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000;283(9):1145-50.
18. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000;283(9):1151-8.